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Background: The hereditary hemorrhagic telangiectasia syndrome (HHT), also known as the Rendu–Osler-Weber
syndrome is a multiorganic vascular disorder inherited as an autosomal dominant trait. Diagnostic clinical criteria
include: epistaxis, telangiectases in mucocutaneous and gastrointestinal sites, arteriovenous malformations (AVMs)
most commonly found in pulmonary, hepatic and cerebral circulations, and familial inheritance. HHT is transmitted
in 90% of the cases as an autosomal dominant condition due to mutations in either endoglin (ENG), or activin
receptor-like kinase 1 (ACVRL1/ALK1) genes (HHT type 1 and 2, respectively).
Methods: We have carried out a genetic analysis of four independent Spanish families with HHT clinical criteria,
which has permitted the identification of new large deletions in ENG. These mutations were first detected using
the MLPA technique and subsequently, the deletion breakpoints were mapped using a customized copy number
variation (CNV) microarray. The array was designed to cover the ENG gene and surrounding areas.
Results: All tested families carried large deletions ranging from 3-kb to 100-kb, involving the ENG gene promoter,
several ENG exons, and the two downstream genes FGSH and CDK9. Interestingly, common breakpoints coincident
with Alu repetitive sequences were found among these families.
Conclusions: The systematic hybridization of DNA from HHT families, with deletions or duplications, to custom
designed microarrays, could allow the mapping of breakpoints, coincident with repetitive Alu sequences that might
act as “hot spots” in the development of chromosomal anomalies.
Keywords: Hereditary hemorrhagic telangiectasia (HHT), Endoglin deletions, Multiplex ligation PCR assisted assay
(MLPA), Copy number variation (CNV) arrays, Alu repetitive sequencesBackground
The hereditary hemorrhagic telangiectasia syndrome (HHT),
also known as Rendu–Osler-Weber syndrome [1-3] is a
vascular disorder inherited as an autosomal dominant
trait. Careful epidemiological studies have revealed that
HHT affects approximately 1 in 5,000 individuals [4,5]
and is therefore considered to be an inherited rare vas-
cular disease.* Correspondence: cibluisa@cib.csic.es
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reproduction in any medium, provided the orThe clinical symptoms characteristic of HHT are the
so-called Curaçao criteria [2], which help in its diagnosis
when at least 3 of the 4 criteria are present in a patient.
These include: epistaxis (nose bleeds), telangiectasia at
mucocutaneous and gastrointestinal sites, arteriovenous
malformations (AVMs) most commonly found in pul-
monary, hepatic and cerebral circulations, and dominant
familial inheritance [3,6].
HHT is transmitted as an autosomal dominant condition
due to a single mutation in Endoglin (ENG; HHT1) [7],
Activin Receptor-Like Kinase 1 (ACVRL1/ALK1; HHT2) [8],
or MADH4/SMAD4 (JHPT, a combined syndrome of
juvenile polyposis and HHT) [9]. The involvement of all
these genes in the transforming growth factor (TGF-β)al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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There are at least two further unidentified genes that
can cause HHT: HHT3 between 141.9 and 146.4 Mb on
chromosome 5q [3,11] and HHT4 on chromosome 7p
between D7S2252 and D7S510.130 [12].
The genes mutated in HHT encode proteins that me-
diate signaling by the TGF-β superfamily. Members of
this superfamily such as TGF-βs, bone morphogenetic
proteins (BMPs), activins, nodals, growth/differentiation
factors (GDFs) and inhibins regulate diverse cellular
functions by binding to a heteromeric complex of type I
and type II transmembrane serine/threonine kinase re-
ceptors [13]. In the TGF-β signaling cascade, the type II
receptor with very high ligand affinity, co-operatively re-
cruits and transphosphorylates the type I receptor by
direct contact with the ligand-modified N-terminus of
TβRI [14]. In Smad-dependent TGF-β pathways, the
type I receptor subsequently phosphorylates and acti-
vates receptor-associated (R)-Smads, according to the re-
ceptor complex involved. R-Smads bind to Smad4 and
translocate to the nucleus where they influence tran-
scriptional activity with co-activators and co-repressors.
In endothelial cells, upon ligand binding, TβRII can
associate with two different TGF-β type I receptors
ALK-5 or ALK-1 [15]. Endoglin is an auxiliary receptor
that modulates both associations in an opposite manner.
Thus, while endoglin promotes signaling through ALK-
1, it inhibits the ALK-5 pathway [16,17]. In turn, ALK-1
and ALK-5 activate distinct Smad pathways, resulting in
opposing endothelial cell responses in terms of prolifer-
ation, migration, and pro- or anti-angiogenic gene ex-
pression [15,18,19].
So far, more than 600 different mutations have been
found in ENG and ACVRL1 in HHT families (HHT muta-
tion database; http://www.arup.utah.edu/database/hht/).
Mutations range from single base-pair changes to major
deletions of multiple exons. Recently, pathogenic muta-
tions affecting the 5’ UTR region of ENG leading to new
translation initiation sites (TIS) dominant over the nor-
mal endoglin TIS have also been described [20,21].
In the present study we describe for the first time, a
series of 4 families, harboring 4 different independent
mutations in the ENG gene, not described so far in lit-
erature. All of them were large deletions starting in the
5’ upstream region of ENG, and spanning just the pro-
moter region, one or several exons, or even a big 100-Kb
deletion encompassing the whole ENG gene and the two
downstream genes FGSH and CDK9. These mutations
were first detected by MLPA technique, and subsequently
the breakpoints were characterized using a customized
copy number variation (CNV) microarray, designed to
cover ENG and flanking sequences. Interestingly, common
breakpoints located within “Alu” sequences were found
among these families. To the best of our knowledge, thisis the first time a fine mapping of a series of deletion
mutations is described in HHT taking advantage of a
customized CNV/CGH microarray.
Methods
Patient samples
Blood samples of 4 independent families from Spain
with clinically confirmed HHT (the presence of three or
four Curaçao criteria) were subjected to molecular diag-
nostics. The clinical data of these patients were obtained
from screening performed in the Spanish HHT reference
Center of Sierrallana, or alternatively from the referring
physicians. Informed consent was obtained from all the
patients.
Ethics statement request
Human blood samples and clinical data reported in this
manuscript were obtained with the prior approval of the
appropriate ethics committees of the CSIC for the re-
search conducted in the Centro de Investigaciones Bio-
lógicas (CIB, Madrid), the CEIC (Clinical Research Ethics
Committee) of the Cantabrian Health Service for patients
attending the Hospital of Sierrallana (Torrelavega, Santander,
Cantabria), and the Medical Genetics department of the
Hospital Valdecilla (Santander, Cantabria). Research was car-
ried out in compliance with the Helsinki Declaration (http://
www.wma.net/en/30publications/10policies/b3/index.html),
keeping the results strictly confidential, with number
codes for the identification of patients.
DNA extraction and mutation analysis
DNA was extracted from peripheral blood using stand-
ard procedures. Each coding exon and its flanking in-
tronic sequences were amplified by PCR and sequenced
for each of the two genes (ENG and ACVRL1). Primer
sequences and PCR conditions have already been reported
[10,22] and are available upon request. PCR products were
run on 1.5% agarose/1 × TAE gels and purified using a
PCR purification kit (Millipore, Germany). The PCR prod-
ucts were then sequenced in forward and reverse orienta-
tion on an Applied Biosystems sequencer using the dye
terminator cycle sequencing kit according to the manufac-
turer’s instructions. If no mutation was found either in
ENG or ALK1, MLPA was performed. DNA concentration
was measured for each sample using a Nanodrop spectro-
photometer. At the same time the DNA integrity was
checked by agarose gel electrophoresis (0.8% in TAE).
Multiplex ligation-dependent probe amplification (MLPA)
MLPA [23] was performed with 200 ng of genomic
DNA according to the manufacturer’s instructions using
the P093 Salsa MLPA HHT/PPH1 probe set (MRC-Holland,
Amsterdam, The Netherlands). Probe amplification products
were run on an ABI PRISM 310 Genetic Analyzer using
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systems). Data were analyzed using Coffalyser MLPA data
analysis software, and a relative copy number was ob-
tained after normalization of peaks against controls.
Values between 0.75 and 1.3 were considered to be within
the normal range. (LLC, State College, PA). Because of
variations in assay performance, we used dosage ratio
values of ≤0.7 as our boundaries.
Characterization of the breakpoints
Breakpoints were studied using a custom designed CGH
microarray (Agilent) to detect copy number variations.
A tiling microarray was designed with eArray (Agilent).
The array contains a total of 15,744 probes, including:
i) 7,568 probes of ENG; ii) 3,927 probes from the rest of
chromosome 9; iii) 1,262 probes included for normal-
ization; and iv) 2,987 probes as Agilent controls. A total of
7,568 probes were selected in the region of interest (chr9:
130548305–130661871, hg19) covering the ENG gene and
the surrounding upstream and downstream sequences to
complete a total area of 113-Kb, with the ENG gene in its
center (Figure 1). Probes were designed with an average
probe spacing of 15-bp, and allowed to vary in size (from
45- to 60-mer) in order to maintain their Tm about 80°C.
The rest of the chromosome 9 was covered with 3,927
additional probes. For normalization purposes during data
analysis, 1,262 probes, distributed among all chromo-
somes, were also included. 2,987 probes were Agilent con-
trols. A probe performance score was assigned to each
probe by the software.
Labeling was carried out according to manufacturer
protocol l (Agilent Oligonucleotide Array-Based CGH for
Genomic DNA Analysis, v6.3). Briefly, eight genomic DNA
samples, including four controls (non HTT patients), were
Cy5 labeled and co-hybridized with a sex matched, Cy3 la-
beled human genomic reference DNA (Promega). After
hybridization, arrays were washed and the signal for each
probe was captured (scanned) with an Agilent scanner.Figure 1 Schematic representation of the probes covering the ENG g
The probes overlap centered at ENG (tiling microarray).Images were analyzed using Agilent Feature Extraction
v10.7 software. The quality of the hybridization was esti-
mated by the DLRS parameter, indicating the dispersion
among the hybridization signaling of the probes. In all
cases, good DLRS values, between 0.1 and 0.2 were
obtained.
Finally, raw data were analyzed with Agilent Genomic
Workbench 6.5. Pre-processing steps were done by ap-
plying GC correction and centralization. Probes with
scores below 0.5 were filtered out. Aberration calling
was done with the ADM-2 algorithm with a threshold of
0.6. An aberration was considered when there were at
least 5 consecutives probes with a minimum absolute
average log ratio of 0.25. The breakpoint regions were
inspected with a UCSC Genome Browser, using the Re-
peat Masker database to identify repeated elements.Results
Correlation between the presence of deletions in ENG
and the clinical phenotype
Table 1 shows the clinical symptoms and genetics of
HHT patients belonging to 4 independent families. The
clinical symptoms are always accompanied by the pres-
ence of the mutations commented on below. Those pa-
tients with known genetics, but referenced in Table 1 with
“no data” for the different clinical HHT symptoms, had
not undergone a complete clinical screening, whereas pa-
tients with complete data were either, screened in the
Spanish HHT Reference Center of Sierrallana, or else-
where. In these families, there was a perfect phenotype-
genotype correlation between clinical criteria and the find-
ing of mutations in ENG. Exceptions to this rule were
children and teen-agers, most of them without relevant
epistaxis, with no telangiectases, and not subjected to
the complete HHT protocol of clinical screening. Close
relatives with no clinical symptoms were also genetically
tested.ene and its flanking regions on the human chromosome 9.
Table 1 Genotype-phenotype correlation in 4 families with HHT
Family Epistaxis Telangiect PAVMs CAVMs HAVMs GB Genetics
NMEx
JCG Yes Yes Yes No No No Δ Promoter ENG
PCG Yes Yes No No No No Δ Promoter ENG
MJCS Yes Yes Yes No No No Δ Promoter ENG
VAC Yes Yes No No No No Δ Promoter ENG
198
198/01/11 Yes Yes Yes No No No Δ Promoter + exon 1 ENG
198/02/11 Yes Yes No data No data No data No data Δ Promoter + exon 1 ENG
198/03/11 3 y No No No data No data No data No data Δ Promoter + exon 1 ENG
71
71/02/08 Yes Yes Yes No Yes Yes Δ Promoter + exons 1-2-3 ENG
71/03/11 No data No data No data No data No data Yes Δ Promoter + exons 1-2-3 ENG
71/04/11 No data No data No data No data No data No data Δ Promoter + exons 1-2-3 ENG
71/08/1113 y No No data Yes No data No data No data Δ Promoter + exons 1-2-3 ENG
71/09/1114 y Yes No data Yes No data No data No data Δ Promoter + exons 1-2-3 ENG
71/12/11 6 y No No data No data No data No data No data Δ Promoter + exons 1-2-3 ENG
GUM
MCDV Yes Yes Yes Yes* No No #Promoter and complete allele ENG (−9 kb + all exons)
JMVD Yes Yes No data No data No data No data #Promoter and complete allele ENG (−9 kb + all exons)
JDHV Yes Yes No data No data No data No data #Promoter and complete allele ENG (−9 kb + all exons)
E, stands for epistaxis, and T for telangiectases. PAVM, CAVM, HAVM stand for pulmonary, cerebral and hepatic arteriovenous malformations, respectively.
GB means gastric bleeding. *patient MCDV had a brain abscess in addition to CAVMs. Δ stands for deletion. # stands for complete deletion of gene.
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Family NMEx, comes from Navalmoral de la Mata, a
town in Extremadura, western Spain. These patients
were referred to our HHT unit from the local hospital of
this town, because they presented epistaxis, telangiecta-
sia, and some of them also suffered from internal ar-
teriovenous malformations (Table 1). After amplification
and sequencing of all exons and intron-exon boundaries
of ENG and ACVRL1 genes, no mutation was found.
Therefore, according to the protocol established in our
HHT unit, an MLPA was performed. By comparing pa-
tient JCG with a control sample (Figure 2A), it can be
seen that only the peak corresponding to the ENG
MLPA probe annealing in the proximal promoter region
appears affected. The same result was obtained for the
four members of this family, whose clinical data are
listed in Table 1, while relatives without HHT criteria,
did not show any alteration in the MLPA (data not
shown). Notably, no mutation involving a deletion of the
ENG promoter has been reported in HHT so far. The
possible existence of a polymorphism in the hybrid-
ization area of the corresponding MLPA probe, which
could prevent primer annealing, was discarded by se-
quencing the proximal promoter region, from -450 bp to
the transcription start (data not shown).Family 198
In this family from northern Spain, a total of 3 members
with clinical diagnosis of HHT were subjected to the
normal protocol of PCR amplification and sequencing,
but no mutations in either ENG or ACVRL1 were ob-
served. As in the case of family NMEx, MLPA analysis
was carried out, and a deletion involving the promoter
and exon 1 of ENG was found. In Figure 2A, bottom
panel, a representative chromatogram of an affected
family member (198/01/11) reveals that peaks corre-
sponding to promoter and exon 1 are both decreased in
comparison with a control DNA.
Family 71
A total of 6 members, 3 adults and 3 children, were gen-
etically screened. All three adults fulfilled the clinical
Curaçao criteria. As in previous families, while the PCR
and sequencing did not reveal any point mutation or
short duplication/deletion, the MLPA showed a large de-
letion encompassing the promoter and exons 1 to 3 of
ENG (Figure 2B). Moreover, the 3 children had no vis-
ible clinical signs of HHT, but their positive genetic test
result prompted a subsequent, in depth clinical examin-
ation and led to the finding of pulmonary AVMs in two
of them.
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Figure 2 (See legend on next page.)
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Figure 2 MLPA results of the 4 different families analyzed in the present work. A) Control and chromatogram representing the family with
promoter deletion (NMEx) and with promoter and exon 1 deletion (198). B) Control chromatogram and family 71 exhibiting deletion of promoter
and exons from 1–3. C) Family GUM with whole deletion of ENG gene including the promoter. In the chromatograms the height of the peaks is
proportional to the amplification of the corresponding exon probe. The affected exons are indicated by arrows in each case.
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Three members of a family from Madrid were diagnosed
with clinical criteria of HHT. The conventional genetic
analysis did not find any mutation, but MLPA analysis
(Figure 2C), revealed the complete absence of one ENG
allele starting at 9 kb upstream from the transcription
start site, suggesting that these patients were hemizy-
gous, at least for ENG.
Characterization of the breakpoints for the ENG deletion
mutants
In all these families there were common properties that
made them especially interesting for further analyses: all
of them contained deletions in ENG, not previously
published in HHT literature, and all these deletions
started on one side of the promoter region of ENG.
Thus, it was of interest to analyze: i) the mapping of the
different deletions; ii) whether there were common
breakpoints; and iii) whether there was a common
characteristic shared by these regions prone to breaking.
Accordingly, breakpoints were studied with a custom
designed tiling CGH microarray (Agilent) to detect copy
number variations.
A schematic representation of the final deletion
map, for each family, and the genes affected is shown
in Figure 3.
A more detailed view of the individual hybridization of
each DNA sample to the probes of the array can be seen
in Additional file 1: Figure S1. The upper part of the
panels in Additional file 1: Figure S1 represents a general
view of the hybridization signals within the 9q34.11GUM
SH2D3C
CDK9
FPGS
ENG
50 kb
Figure 3 Schematic representation of the hybridization results of the
9q34.11. In 198, a 3,139-Kb deletion encompassing promoter and exon 1
3 of ENG. In GUM a 100,730 Kb deletion covering from the proximal promo
NMEx, a 9,313-Kb deletion of ENG promoter. Arrows mark the direction of tregion. At the bottom, a zoom of the region containing
the copy number alteration is presented in more detail.
A shadow box over a crowd of points represents the area
where the algorithm has detected a copy number alter-
ation. A minimum of 5 probes, hybridizing in the same
manner and placed in the same area, are required to de-
fine a significant copy number alteration over a chromo-
some position.
Table 2 shows a summary of the results obtained from
the microarray, showing the exact breakpoints for each
deletion found in the four different families. Deletions
affecting coding regions of ENG include: i) the smallest
deletion of 3,139-Kb, affecting the proximal promoter
and exon 1 of ENG (family 198); ii) an intermediate size
deletion encompassing 28,744-Kb, starting at the same
point of the proximal promoter as the previous one, and
spanning exons 1 to 3 of ENG (family 71); and iii) the
largest deletion, spanning from 9 kb upstream from the
transcription start site of ENG, the whole ENG gene,
and two adjacent ENG-downstream genes FPGS, CDK9
and, at least, partially SH2D3C (family GUM). Further-
more, a deletion affecting only the upstream region of
ENG, which does not include any coding region, com-
prises 9,313-Kb, from the same position as in the case of
the largest deletion of the GUM family in the distal pro-
moter region to position -28 bp before the transcription
start for ENG (family NMEx).
Interestingly enough, these 4 different deletions have
some breakpoints in common: two of them start 9.3-Kb
upstream of the ENG transcription start site, and the
other two start approximately 900-bp upstream from the71
198
NMEx
hg19
AK1
different HHT1 families containing deletions in chromosome
of ENG; in 71: a 28,744-Kb deletion including promoter and exons 1 to
ter of ENG, the whole ENG gene, and FPGS, CDK9, SH2D3C genes. In
ranscription of the genes.
Table 2 Deletion break-points for HHT families
Sample Cytoband Ins/Del Molecular position Size Regions deleted Affected genes
JGC 9q34.11 Del 130,617,254-130,626,567 9,313 Kb Promoter 5' upstream ENG Promoter ENG
198/01/11 9q34.11 Del 130,615,100-130,618,239 3,139 Kb Promoter and Exon 1 ENG ENG
71/03/11 9q34.11 Del 130,589,495-130,618,239 28,744 Kb Promoter and Exon 1–3 ENG ENG
MCVD 9q34.11 Del 130,525,837-130,626,567 100,730 Kb 9.3 Kb promoter 5’ upstream,
whole ENG and surroundings
SH2D3C, FPGS, CDK9c ENG
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ence of “hot-spots” for chromosomal rearrangements in
these regions.
To characterize the nature of these regions prone to
“breaking”, we studied the sequences surrounding the
common breakpoints for the deletions, on the assumption
that regions containing repeated elements are more likely
to break. In order to get more insight into the sequence
structure of the breakpoints we analyzed these regions in
more detail with the Repeat Masker tool for repeat se-
quences of the UCSC Genome Browser. Figure 4A shows
different repeat elements around the breakpoint common
to families 198 and 71. Among them, the Alu element
AluSz, that contains the common breakpoint, is locatedFigure 4 Map of the common breakpoints for the independent deleti
198, located around 900-bp upstream of the transcription start of ENG gen
region are represented. B) Map of the common breakpoint for the inde
upstream from the transcription start of ENG gene. Repetitive elements
occurs from right to left.900-bp upstream of the transcription start, and was first
described for the ENG promoter by Rius et al. [24].
The other breakpoint, found in the remaining two
families (GUM and NMEx), is located further upstream
from the ENG promoter. In this case, there is an accu-
mulation of repeat elements surrounding the breakpoint,
including mostly Alu sequences and also a LINE1 elem-
ent (L1ME2z), as shown in Figure 4B. These results sug-
gest that breakpoints upstream of ENG are positioned
where mobile or repeated elements are located.
Discussion
Most of the mutations involved in the pathogenesis of
HHT are single base-pair substitutions or small duplications/ons found in the different families. A) Map for the families 71 and
e. Repetitive element sequences, including Alu elements, found in this
pendent deletions found in families NMEx and GUM, placed 9.3-Kb
and Alu sequences are shown. Note that transcription of ENG
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HHT identified for ENG, 17% nonsense, 30% missense,
25% splice, and 28% frameshift mutations, whereas for
ACVRL1 17% were nonsense 60% missense, 7% splice,
and 15% frameshift mutations [25].
When no mutations are found in either ENG or
ACVRL1 by PCR and sequencing of coding exons and
intron boundaries, then the multiplex quantitative PCR
(qPCR)-based assay method MLPA is the standard rou-
tine technique applied to samples. MLPA allows the
identification of dosage for proximal promoter and
exons in the HHT-related genes, including deletions or
duplications of whole exons. However, this method does
not yield a systematic mapping of the breakpoints corre-
sponding to these chromosomal aberrations. So far, mu-
tations affecting the copy number variation of ENG or
ACVRL1 causing HHT, as evidenced by MLPA, repre-
sent around 7% of all the pathogenic mutations detected
in these genes [25,26].
More recently, CNV custom CGH arrays have emerged
as an alternative technique to MLPA to detect large dele-
tions or insertions, with the advantage of allowing the
mapping and detailed analysis of breakpoints. Thus, this
technique can reveal the presence of “hot spots” or points
prone to breaking, which may lead to common mutation
events in independent families, and coincident with re-
petitive sequences. In the present work we have identified
and mapped four large deletions affecting ENG that have
not been previously reported in publications and which
were first detected by MLPA. To the best of our know-
ledge, this is the first time that the breakpoints of large de-
letions in ENG have been mapped in independent HHT
families.
In all cases the deletions started in the region of the
ENG promoter and were the first reported deletions af-
fecting the promoter and implicated in HHT. Interest-
ingly, the affected members of the family NMEx were
heterozygous for a 9-Kb deletion of the promoter expand-
ing up to 28 bp upstream of the transcription initiation
start site. In this case, the loss of the promoter region
leading to a hemizygous allele is the likely cause of HHT.
Indeed, the proximal promoter region of ENG plays a crit-
ical role in the basal transcription, mainly through binding
of the transcription factor Sp1 to consensus GC-rich mo-
tifs [24,27]. Additionally, the promoter activity of ENG
can be regulated by several physiological stimuli. In this
regard, Sp1 can directly bind, in protein-DNA complexes,
to the transcription factors KLF6, Smad3/Smad4 or HIF-
1α, activated by vascular injury [28], treatment with
TGF-β1 [27] or hypoxia [29], respectively. In turn, the mul-
ticomplex formed by all these transcription factors leads to
synergistic transcriptional cooperation with the promoter
activity of ENG. Therefore, basal and stimuli-dependent
transcription of ENG would be abrogated in those HHTpatients harboring a promoter deletion, contributing to the
haploinsufficiency of ENG.
HHT patients from family GUM are hemizygous not
only for ENG, but also for the genes FPGS, CDK9 immedi-
ately downstream, and at least part of SH2D3C. However,
the additional heterozygous deletion of these genes does
not seem to affect the severity or type of clinical symp-
toms. This would explain the lack of a reported pathology
associated with heterozygous mutations of these genes in
relevant scientific publications.
The detailed mapping of the deletions has revealed in-
teresting hot spots in ENG introns and their upstream
promoter region where common breakpoints have been
found. Thus, we have identified two different break-
points placed in non-coding regions corresponding to
allocation sites for Alu mobile elements, and both de-
rived from independent recombination events in differ-
ent families. One of the breakpoints is within a cluster
of Alu sequences, 9-Kb upstream of the ENG transcrip-
tion start site (Figure 4B), and the other is on an Alu
element, placed 900 bp upstream of the ENG transcrip-
tion start site (Figure 4A). In agreement with this find-
ing, Wooderchak et al. [30] described the breakpoints
for two deletions affecting ENG in a single HHT family,
one of them encompassing exon 3 and the other involv-
ing exons 4 to 7 [30]. Interestingly, both deletions share
a common breakpoint location in intron 3. Further-
more, a large 117-bp repetitive DNA sequence was
identified near the breakpoints in introns 2, 3, and 7 of
ENG. These repetitive sequences had a sequence iden-
tity of approximately 85%, had similar orientation, and
were each found to contain Alu elements. These results
suggest that this type of mobile element is a common
target of recombination in HHT genes. Supporting this
view, Alu sequences have been involved in the gener-
ation of genomic deletions in different human genetic
disorders [31,32]. Further studies have yet to be carried
out to better understand the mechanisms of recom-
bination in HHT. In this regard, it would be interesting
to screen the published deletions and duplications
found in ENG and ACVRL1, taking advantage of the
CNV array technique to obtain a map of deletions or
duplications from as little as 15-bp to many kilobases.
Conclusions
The systematic hybridization of DNA from HHT families,
with deletions or duplications, to custom designed micro-
arrays, could allow the mapping of breakpoints, coincident
with repetitive Alu sequences that might act as “hot spots”
in the development of chromosomal anomalies. New data,
generated this way, would then enrich the HHT mutation
databank by including the specific sequences of the
chromosomal rearrangements, in addition to the current
mutations.
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Additional file 1: Figure S1. Hybridization results of the different DNAs to
the CGH/CNV array. A) Hybridization results from sample 198/01/11: 3,139-Kb
deletion chromosome 9q34.11: promoter and exon 1 of ENG. B) Hybridization
results from sample 71/03/11, a 28,744-Kb deletion chromosome
9q34.11, including promoter and exons 1 to 3 of ENG. C) Hybridization
results from sample GUM: 100,730-Kb deletion chromosome 9q34.11:
promoter ENG, FPGS, CDK9 and SH2D3C genes. D) Hybridization results
from sample NMEx: 9,313-Kb deletion chromosome 9q34.11: promoter
of ENG. In all cases, the general view of chromosome 9 with the probe
hybridization is presented above, and below the region containing the
deletion is magnified to show details.
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